Of mice and M&A: Horizon buys Sage Labs

The U.K.'s Horizon Discovery has snapped up St. Louis-based Sage Labs for $48 million in cash and stock. The deal delivers a leading developer of mouse models for preclinical drug R&D. The Cambridge-based biotech went public last March, raising £68.6 million as well as exciting fresh hopes for the U.K.'s life sciences field. Story

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.